Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Glucotrack, Inc.IGAP · Entity 8422 | Vice President of Operations | April 13, 2017 | April 14, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Glucotrack, Inc.
Report date April 13, 2017 · Filed April 14, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.50 · Expires 2027-04-13 | Direct | 361,875 |
Reported balance
After 2017-04-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-04-13 · Grant · Acquired 361,875 · Balance 361,875 F1: On a fully diluted basis. F2: The options shall vest over a three-year period commencing on April 13, 2017. |
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.75 · Expires 2027-04-13 | Direct | 266,617 |
Reported balance
After 2017-04-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-04-13 · Grant · Acquired 266,617 · Balance 266,617 F3: The option shall vest 50% upon CFDA approval and 50% upon FDA approval. |
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.50 | Direct | 25,000 |
Reported balance
After 2017-04-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-04-13 · Grant · Acquired 25,000 · Balance 25,000 F4: Pursuant to the employment agreement entered into by the Company's wholly owned subsidiary, A.D. Integrity Applications Ltd. and the Reporting Person, the grant of the options to purchase common stock is subject to the Company reaching certain corporate development milestones. F5: The option shall vest over a three year period beginning on the date of grant as set forth in Note 4. F6: The option shall expire upon the ten (10) year anniversary of the date of grant as set forth in Note 4. |
Filing footnotes · ownership attribution and instrument terms
F1: On a fully diluted basis.
F2: The options shall vest over a three-year period commencing on April 13, 2017.
F3: The option shall vest 50% upon CFDA approval and 50% upon FDA approval.
F4: Pursuant to the employment agreement entered into by the Company's wholly owned subsidiary, A.D. Integrity Applications Ltd. and the Reporting Person, the grant of the options to purchase common stock is subject to the Company reaching certain corporate development milestones.
F5: The option shall vest over a three year period beginning on the date of grant as set forth in Note 4.
F6: The option shall expire upon the ten (10) year anniversary of the date of grant as set forth in Note 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 13, 2017 Filed Apr 14, 2017 20:20 UTC | Glucotrack, Inc. IGAP · Entity 8422 | GrantOption (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $4.50 | $0.00 |
DisclosureSEC source: 0001178913-17-001121 · zk1719817.xml · derivative · entry 3 Malka David · CIK 0001556758 · Vice President of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock, par value $0.001 per share · 25,000 shares Expires not disclosed F4 · kind: Pursuant to the employment agreement entered into by the Company's wholly owned subsidiary, A.D. Integrity Applications Ltd. and the Reporting Person, the grant of the options to purchase common stock is subject to the Company reaching certain corporate development milestones. F5 · derivative.exercise_date: The option shall vest over a three year period beginning on the date of grant as set forth in Note 4. F6 · derivative.expiration_date: The option shall expire upon the ten (10) year anniversary of the date of grant as set forth in Note 4. Read SEC document |
| April 13, 2017 Filed Apr 14, 2017 20:20 UTC | Glucotrack, Inc. IGAP · Entity 8422 | GrantOption (Right to Buy) · Derivative | 266,617 | $0.00 Strike: $7.75 | $0.00 |
DisclosureSEC source: 0001178913-17-001121 · zk1719817.xml · derivative · entry 2 Malka David · CIK 0001556758 · Vice President of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,617 Underlying: Common Stock, par value $0.001 per share · 266,617 shares Expires 2027-04-13 F3 · derivative.exercise_date: The option shall vest 50% upon CFDA approval and 50% upon FDA approval. Read SEC document |
| April 13, 2017 Filed Apr 14, 2017 20:20 UTC | Glucotrack, Inc. IGAP · Entity 8422 | GrantOption (Right to Buy) · Derivative | 361,875 | $0.00 Strike: $4.50 | $0.00 |
DisclosureSEC source: 0001178913-17-001121 · zk1719817.xml · derivative · entry 1 Malka David · CIK 0001556758 · Vice President of Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,875 Underlying: Common Stock, par value $0.001 per share · 361,875 shares Expires 2027-04-13 F1 · shares: On a fully diluted basis. F2 · derivative.exercise_date: The options shall vest over a three-year period commencing on April 13, 2017. F1 · derivative.underlying_shares: On a fully diluted basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.